Human papillomavirus (HPV) vaccination in the US continues to lag well behind the national
goal of 80% series completion. There have been many efforts to identify factors associated …

While the HPV vaccine is being touted by many as one of the greatest breakthroughs in
cancer prevention, some public-health experts are concerned that the rush to mandate the …

Background: Rates of routine human papillomavirus (HPV) vaccination of adolescent males
in the United States are low. Leading health organizations advocate consistent and strong …

The Centers for Disease Control and Prevention Advisory Committee on Immunization
Practices (ACIP) recommends routine human papillomavirus (HPV) vaccination at ages 9 to …

CMAJ• August 28, 2007• 177 (5) 485 about 70% of infected women, and within 2 years for
90%. 7 Thus, HPV infection and cervical cancer must not be conflated: cervical cancer will …

Background Human papillomavirus (HPV) vaccination has been routinely recommended at
age 11–12 years in the United States for females since 2006 and males since 2011 …

Although protection against HPV infection is lower in individuals aged 26 years and older,
emerging data have suggested a potential role for vaccination in the secondary prevention …

The human papillomavirus (HPV) vaccine is effective at reducing the incidence of cervical
cancer caused by HPV. Studies have shown that 1 dose of the HPV vaccine offers …

The results of the 2014 US National Immunization Survey–Teen (NIS-Teen) indicated very
modest increases in human papilloma virus (HPV) vaccination rates for 13-to 17-year-old …

This policy brief looks at awareness and utilization of the Human Papillomavirus vaccine
among girls age 13 years and older as well as among young women. Interest in receiving …